The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of developing second cancers; we aimed to evaluate the incidence of second malignancies in patients with CML using Surveillance, Epidemiology, and End Results Program data. We identified 13,276 patients with CML newly diagnosed in 2001–2014...
BACKGROUND
The achievement of a sustained deep molecular response is a goal of increasing relevance because it opens the possibility of treatment discontinuation. The objective of this analysis was to develop a prediction model for a sustained molecular response with BCR‐ABL1 level <0.0032% on the international scale (MR4.5) for at least 2 years according to BCR‐ABL1 levels achieved within the...
BACKGROUND
Both dasatinib and nilotinib are approved frontline therapy for chronic myeloid leukemia in chronic phase (CML‐CP) based on randomized trials compared with imatinib. However, no head‐to‐head comparison of dasatinib and nilotinib has been conducted in patients with newly diagnosed CML‐CP.
METHODS
The authors conducted a propensity score (PS) matched comparison of patients with CML‐CP...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.